HSCT (Hematopoietic Stem Cell Transplant) is an intense chemotherapy treatment for multiple sclerosis. Its goal is to “reset” the immune system by eliminating it and then re-culturing it, using stem cells. Mesenchymal stem cell (MSC) therapy has significant potential as a treatment option for multiple sclerosis (MS). While more research is needed to understand their long-term effectiveness, peer-reviewed studies have shown promising results in reducing inflammation and promoting tissue repair in patients with multiple sclerosis.
Stem cell therapy is any treatment that uses or targets stem cells, which are the types of cells that differentiate into many different specialized cells in our body. Stem cells are found in both embryos and adults. Learn what they are and how they can be used to treat multiple sclerosis. The goal of AHSCT is to stop the damage caused by multiple sclerosis to the brain and spinal cord by “annihilating” the faulty immune system with a high dose of chemotherapy.
Once destroyed, the immune system is rebuilt using blood and bone marrow stem cells that would have been extracted from the patient's own blood before chemotherapy. The regenerating immune system then effectively “restarts”. It's this mechanism that allows inflammation in the brain and spinal cord that causes problems with vision, mobility, sensitivity, balance, bladder, cognition, fatigue, and pain to decrease and heal. Stem cells can develop into different types of cells in the body.
Hematopoietic stem cells produce blood cells. Some doctors use a type of stem cell treatment called a hematopoietic stem cell transplant (HSCT) to treat RRMS. However, more research is needed to know how well HSCT works to combat it. The FDA approved Tyruko (natalizumab), a previously approved biosimilar to Tysabri, as a treatment for relapsing forms of multiple sclerosis.
Most of these therapies are being studied in clinical trials. The only stem cell therapy that should currently be accepted as a treatment for MS outside of clinical trials is autologous hematopoietic stem cell transplantation (aHSCT), for which there is sufficient evidence of the potential benefits, risks and side effects. That means you've had severe relapses of multiple sclerosis and your symptoms have rapidly worsened because other treatments haven't helped. These benefits appear to be of particular clinical importance, as they were seen in patients with progressive multiple sclerosis who did not respond to conventional immunotherapies and for whom there are limited treatment options.
The trial will measure how good and safe AHSCT is compared directly to the most recent leading treatments for multiple sclerosis. Over the next five years, Colette tried several treatments for her multiple sclerosis, but nothing could reduce the worsening of relapses and the damaging spasms that prevented her from walking and often caused her to collapse when she got out of bed. The BEAT-MS study is a phase III clinical trial in which the safety, efficacy, and cost-effectiveness of aHSCT will be directly compared with the best available treatments that have proven benefits for people with active relapsing MS.
In a recent double-blind phase II, randomized, placebo-controlled trial in 48 patients conducted in Israel, mesenchymal stem cell therapy was found to improve MS symptoms in approximately 73% of participants.
.Mesenchymal stem cells (MSCs) can regenerate scar tissue (damaged myelin sheath) in affected neurons. Mesenchymal stem cells (MSCs, sometimes referred to as mesenchymal stromal cells or bone marrow stromal cells) are adult stem cells that can produce many different types of cells, including muscle, cartilage, and nerve cells. For people with multiple sclerosis for whom first-line therapies haven't worked, HSCT offers the most exciting treatment to date: a real breakthrough in the fight against this debilitating condition. It's important for people with multiple sclerosis to have the best information available about stem cell therapy to make decisions related to this complex issue.
If you're interested in stem cell therapy, an MS specialist can answer your questions and provide guidance. Mesenchymal stem cells (MSCs) can promote remyelination and improve myelin repair when transplanted into animal models of demyelination. International Multiple Sclerosis Federation, third floor, Skyline House, 200 Union Street London SE1 0LX. Every person is different, but when treatment is successful, the immune system should regain its full strength within 3 to 6 months.
Mesenchymal stem cell therapy (MSCT) offers patients the option of effective treatment without the risk of chemotherapy or who may be too poor to undergo a hematopoietic stem cell transplant (HSCT). .
